Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Princeton, New Jersey 08540


The purpose of this study is to demonstrate the superiority of SonoVue®-enhanced ultrasound versus unenhanced ultrasound for characterization of Focal Liver Lesions using final diagnosis based on histology or combined imaging/clinical data as truth standard.

Study summary:

Unit of analysis for the outcome measures was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.


Inclusion Criteria: - Male/female. - Provides written Informed Consent and is willing to comply with protocol requirements. - Is at least 18 years of age. - Has at least 1 focal liver lesion (FLL) (target lesion) requiring work-up for characterization. Target lesions may include those: - Incidentally detected, - In subjects with chronic hepatitis or liver cirrhosis, - In subjects with known history of malignancy. - Is scheduled for surgical removal or biopsy of the target lesion from 24 hours to 30 days after the SonoVue® administration OR - In case tissue biopsy is not indicated nor surgery planned, is scheduled for or has performed a contrast-enhanced (CE) CT and/or CE-MRI of the target lesion from 30 days to 48 hours prior to or from 24 hours to 30 days after the administration of SonoVue®. Exclusion Criteria: - Has an acoustic window insufficient for adequate ultrasound examination of the liver. - Has a FLL that cannot be identified with unenhanced ultrasound. - Has received or is scheduled for antineoplastic chemotherapy or an invasive procedure in the time period between test procedures and truth standard assessments which may have modified the target lesion. - Is receiving any other contrast medium, within the 48 hours before and up to 24 hours following the administration of SonoVue®. - Has previously been enrolled in and completed this study. - Known right to left cardiac shunt, bidirectional or transient. - Has any known allergy to 1 or more of the ingredients of the investigational product (sulfur hexafluoride or to any components of SonoVue®). - Has any contraindication to 1 of the planned imaging procedures (ultrasound, CT or MRI), e.g., implants, claustrophobia, inadequate medical conditions etc. - Has received an investigational compound within 30 days before admission into this study. - Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations. - Is determined by the Investigator that the subject is clinically unsuitable for the study. - Is a pregnant or lactating female. Exclude the possibility of pregnancy by: - testing on site at the institution serum beta-human chorionic gonadotropin (βHCG) within 24 hours prior to the start of SonoVue® administration, - surgical history (e.g., tubal ligation or hysterectomy), - post menopausal with a minimum 1 year without menses.



Primary Contact:

Study Chair
Maria Luigia Storto, M.D.
Bracco Diagnostics, Inc

Backup Contact:


Location Contact:

Princeton, New Jersey 08540
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.